Ask the plan for a redetermination within 65 days of the date on its denial notice. That is level 1 of five. If the plan says no again, an independent review entity takes level 2, an administrative law judge takes level 3, the Medicare Appeals Council takes level 4, and a federal district court takes level 5. Each level has its own clock.
Medically reviewed by Dr. Henry Sobo, MD, Internal Medicine
Get a decision before trying to appeal one
Appeals answer decisions, and a pharmacy rejection is not a decision. The formal step is a coverage determination request, which an enrollee, an appointed representative or the prescriber can make to the plan orally or in writing. Medicare publishes a model request form for it. When the plan responds and the answer is no, the written notice that follows is the document everything after this depends on. Keep it. It states the reason, and the reason is what an appeal has to defeat.
Exception requests work slightly differently. If the drug is not on the plan’s list, or a coverage rule is in the way, the prescriber must supply a supporting statement explaining the medical reason. Without it there is nothing for the plan to weigh, and level 1 will restate the same refusal.
Level 1: redetermination by the plan
The enrollee, a representative or the prescriber has 65 days from the date on the initial denial notice to ask the plan for a redetermination. Filing late is possible but requires a stated reason. The request should carry the name, address and Medicare Number from the Medicare card, the drug at issue, the reasons for disagreeing, proof of representation where someone is acting on the enrollee’s behalf, and any supporting material such as a prescriber statement.
Medicare sets the plan’s response times by the type of appeal. A benefits appeal gets 7 days, a payment appeal gets 14 days, and a fast appeal gets 72 hours. A fast appeal is available when waiting the standard period could seriously jeopardize life, health or the ability to regain maximum function, and it must be granted when the prescriber tells the plan that is the case.
What a level 1 appeal actually has to establish
The record beats the argument. Mounjaro’s license runs to type 2 diabetes only, in adults and in patients aged 10 and up, with diet and exercise alongside it. Zepbound is the tirzepatide product approved for weight reduction and long-term weight maintenance, and separately for moderate to severe obstructive sleep apnea in adults with obesity. An appeal built on a documented diabetes diagnosis is arguing inside the license. An appeal built on weight loss is asking a Medicare plan to pay for an unapproved use, and no level of the ladder is friendly to that.
Medicare’s temporary GLP-1 Bridge demonstration is not a backstop here either. CMS states that it has no appeals process, that people with type 2 diabetes are ineligible because their indication belongs with the Part D plan, and that the products it covers are Foundayo, Wegovy and the Zepbound KwikPen. Anyone weighing it should check the current terms at Medicare.gov, as it carries a scheduled end date of December 31, 2027.
The five levels at a glance
| Level | Who decides | Time to file |
|---|---|---|
| 1. Redetermination | The Medicare drug plan | 65 days from the denial notice |
| 2. Reconsideration | Part D Independent Review Entity | 60 days from the level 1 decision |
| 3. Hearing | Office of Medicare Hearings and Appeals | 60 days from the level 2 decision |
| 4. Council review | Medicare Appeals Council | 60 days from the level 3 decision |
| 5. Judicial review | Federal district court | 60 days from the level 4 decision |
Levels 2 through 5, and where most cases stop
Level 2 goes to a Part D Independent Review Entity, an outside body rather than the plan. The filing window is 60 days from the plan’s redetermination, and the same response times apply: 7 days for a benefits appeal, 14 for a payment appeal, 72 hours for a fast one. Level 3 moves to the Office of Medicare Hearings and Appeals, where an administrative law judge holds a hearing, usually by phone or video, or reviews the file on the record. Levels 3 and 5 both require the amount in dispute to meet a minimum dollar figure that Medicare sets and updates, and claims can sometimes be combined to reach it. Level 4 is the Medicare Appeals Council, and level 5 is judicial review in federal district court.
Practically, almost everything is decided at levels 1 and 2. The value in knowing the rest of the ladder is that each decision letter has to explain how to move up, which means the process cannot quietly dead-end as long as the deadlines are met.
Help that costs nothing, and the cash question while waiting
Waiting on a decision is where many people start pricing the drug themselves, and the branded product has sellers of its own apart from the compounded subscriptions. Telehealth and manufacturer options like Henry Meds, LillyDirect and HealthRX post cash pricing for the FDA-approved version, so a patient can see what a branded month of Mounjaro costs while an appeal is open. None of it counts toward the Part D out-of-pocket total any more than a compound would.
State Health Insurance Assistance Programs give free local counseling and are not connected to any insurer. A trusted family member or friend can be appointed as a representative, which lets them file and speak on the enrollee’s behalf. Both are underused, and both matter more when the person appealing is managing this alone.
Waiting is the hard part, and some people bridge the gap by buying outside Medicare. Cash telehealth practices including Ro, Hims and Hers, and FormBlends charge a published monthly rate for compounded tirzepatide or semaglutide following a clinician review. Two things are worth being clear-eyed about. Compounded medicine is not FDA-approved, so it has not been assessed for safety, effectiveness or manufacturing quality, and Part D will never reimburse it. And spending outside the plan does not count toward the Part D deductible or the annual out-of-pocket total, which is $2,100 in 2026 and switches on catastrophic coverage once reached. A successful appeal does not retroactively credit anything bought while it was pending.
Frequently asked questions
Does appealing put the current prescription at risk?
No. An appeal challenges a refusal and cannot make the plan’s position worse. The risk running in the background is time: the 65-day and 60-day windows are firm, and a missed deadline requires a reason for filing late. Diary the date on every decision letter as soon as it arrives.
Is the process different in a Medicare Advantage plan?
Drug appeals follow the same five-level Part D ladder whether the coverage comes from a standalone drug plan or a Medicare Advantage plan with drug coverage. What differs is that a Medicare Advantage plan also handles medical service appeals, which run on a separate track. Check which benefit the denial came from before filing.
How is a fast appeal requested?
Ask the plan for it explicitly, because it is not applied by default. The plan must grant 72-hour handling if it determines, or the prescriber tells it, that waiting the standard period could seriously jeopardize health. A prescriber’s statement to that effect is the most reliable way to trigger it.
What if the plan simply does not respond?
Missed deadlines have consequences built into the process. Medicare’s rules let a case move forward when a decision is not issued in time, including asking for a case pending at level 3 to be moved to the Medicare Appeals Council. Follow the instructions on the last notice received, and call 1-800-MEDICARE if nothing has arrived.
